Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
November 08, 2023 01:00 ET
|
Ultimovacs ASA
Oslo, November 8, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its third quarter 2023 results today. ...
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
November 02, 2023 03:00 ET
|
Ultimovacs ASA
Oslo, November 2, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its third...
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
November 02, 2023 02:00 ET
|
Ultimovacs ASA
The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of...
Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024
October 31, 2023 02:00 ET
|
Ultimovacs ASA
Patients in the INITIUM study are taking longer than expected to experience cancer progression. Reaching the number of progressing patients required for readout may take several months or even...
Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma
October 25, 2023 11:50 ET
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE Oslo, October 25, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that...
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine
October 23, 2023 01:00 ET
|
Ultimovacs ASA
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, met the study protocol’s predefined threshold for statistical significance and demonstrated a...
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma
October 17, 2023 12:01 ET
|
Ultimovacs ASA
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival benefit with no added toxicities,...
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine
October 12, 2023 01:00 ET
|
Ultimovacs ASA
No confirmed patient deaths occurred in cohort 1 between the 3-year and 4-year follow-up. Oslo, October 12, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage...
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma
October 09, 2023 01:00 ET
|
Ultimovacs ASA
The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU The results from the NIPU study will be presented at the ESMO Congress being held October...
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023
September 27, 2023 10:31 ET
|
Ultimovacs ASA
The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023. Oslo, September 27, 2023 –...